Investment Banking

NOBLE Capital Markets's investment banking team has a singular focus: to exceed our client's expectations by providing the appropriate advice and execution necessary for efficient capital raising, mergers & acquisitions advisory and capital markets support. We leverage our fundamental sector research expertise in healthcare, natural resources, transportation & logistics, technology, media and telecom, along with our firm's three-decade history of capital markets acumen, in the creation of a customized solution for our clients.

Our investment banking team, together with our well-recognized equity research analysts and the equity capital markets group, provide our clients with fundamental capital markets advisory and support - prior, during and most importantly, after a transaction.

IB Services

NOBLE Capital Markets's investment banking team works closely with the management and Board of our corporate clients in order to fully understand operational and financial objectives. With this knowledge our banking team will develop an efficient and effective advisory program which offers a variety of services including:

  • Capital Markets Support
  • Block Trades
  • Mergers & Acquisitions (Buy and Sell-Side)
  • Restructuring & Recapitalizations
  • Sale or Divestitures

NOBLE Capital Markets's investment banking team is able to achieve transactional success for our clients by tapping into our resident expertise in our research verticals, and through our long-standing relationships with leading institutional investors. NOBLE Capital Markets is routinely involved in the following Corporate Finance transactions:

  • Initial Public Offerings (IPOs)
  • Alternative Public Offerings (APOs)
  • Follow-on Offerings
  • Private Placement in Public Companies (PIPE's)
  • Private Placements in Private Companies
  • At The Market Transactions (ATMs)

Merchant Banking

Our Principal Investment focus is primarily on private and small-cap public ($10mill to $50mill market caps) companies in industries within NOBLE's research verticals. Investments are made directly by NOBLE and its affiliates and may also involve syndicate participants. We work to identify those companies with game-changing or superior products and technologies that have management teams with proven track-records of success. Noble structures investments to meet a company's capital needs whether its growth capital, liquidity or debt repayment. Capital commitment ranges from $200k to $2million principal and $2million above with syndicate.

The scope of our Merchant Banking activities includes:

  • Targeting domestic companies within our areas of focus and expertise
  • Analyzing a company's opportunities and assessing its risks within their respective industry
  • Structuring, negotiating and executing the transaction
  • Work in assessing the appropriate time and manner in which to harvest the investment

Post Transaction Support:
NOBLE's Merchant Banking Team works continuously with our portfolio companies to assist the management team and Board of Directors to create value and grow their businesses to facilitate long-term shareholder value. Through our extensive sector research coverage, institutional investor non-deal road shows, equity conferences and market making, we blend a powerful mix of capital markets acumen to procure success.

Transactions

NOBLE's Investment banking team has, on average, more than 25 years' experience in the industry. Transactions drive our business. Building a solid foundation of mutual respect and trust with our customers drives transactions. Here is a selection of some of the companies we've helped over the years.

Scientific Advisory Board

Our Scientific Advisory Board (SAB) is a strategic resource whose experience, relationships and knowledge are utilized throughout NOBLE Life Science Partners to enhance all service offerings. Through the SAB, we have access to world-class healthcare professionals for substantive advice regarding new discoveries, technologies, products, services and developments.

Our SAB is a powerful client offering unique to NOBLE Life Science Partners.

  • Equity Research − enriches our research offerings and expertly positions capital markets deals
  • Institutional Investors − provides solid market insight and unique perspectives
  • Corporate Clients − guides business formation and growth through meaningful assistance with strategic and tactical decisions
  • Assessment of existing products and new product launches
  • Identification of drug development targets, while applying an extensive reach in both Europe and the United States
  • Hands-on guidance in executing licensing opportunities with large-cap companies
  • Strategic market analysis with a goal of identifying the most favorable market opportunity

Investment Banking Team

Richard Giles

Managing Director / Head of TMT and Natural Resources Investment Banking Group

Department:
Investment Banking

E: rgiles@noblecapitalmarkets.com
T: (617) 692-9346
VCard: Richard Giles

Mr. Giles brings to NOBLE Capital Markets more than 30 years of investment banking and capital markets experience. Most recently Mr. Giles was head of the technology group at Stifel Nicolaus and prior to that spent 16 years at A.G. Edwards as head of its emerging growth group that included both Edwards' technology and healthcare practices. During his career he has executed over 100 public financings raising over $4 billion for his clients, including IPOs for companies such as VMWare, COMPAQ, Cardica and ExecuStay. He also has overseen numerous M&A transactions on the buy side as well as the sell side. Mr. Giles received his AB from Harvard College and his MBA from the Harvard Business School. Mr. Giles holds various FINRA licenses and works out of the company's Boston Office.

Richard Giles, Managing Director / Head of TMT and Natural Resources Investment Banking Group

Nathan Cali

Managing Director, Head of Healthcare Investment and Merchant Banking

Department:
Investment Banking
Healthcare

E: ncali@noblelsp.com
T: (561) 994-5723
VCard: Nathan Cali

Nathan Cali has more than 14 years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), medi